Psilocybin - Mindmed/The University Hospital of Basel
Latest Information Update: 28 Sep 2022
At a glance
- Originator The University Hospital of Basel
- Developer Mindmed; The University Hospital of Basel
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Psychotic disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Psychotic-disorders(In volunteers) in Switzerland
- 02 Mar 2022 Efficacy data from a phase I trial in Healthy volunteers released by MindMed
- 30 Nov 2021 Efficacy data from phase I trial in Psychotic disorders released by Mind Medicine